nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Lisinopril—systemic scleroderma	0.737	1	CrCtD
Lisdexamfetamine—Aspartame—Lisinopril—systemic scleroderma	0.196	1	CrCrCtD
Lisdexamfetamine—Lisinopril—ACE—systemic scleroderma	0.000519	1	CrCbGaD
Lisdexamfetamine—Decreased appetite—Captopril—systemic scleroderma	0.000178	0.00268	CcSEcCtD
Lisdexamfetamine—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.000178	0.00268	CcSEcCtD
Lisdexamfetamine—Malnutrition—Lisinopril—systemic scleroderma	0.000178	0.00267	CcSEcCtD
Lisdexamfetamine—Fatigue—Captopril—systemic scleroderma	0.000177	0.00265	CcSEcCtD
Lisdexamfetamine—Anxiety—Leflunomide—systemic scleroderma	0.000176	0.00264	CcSEcCtD
Lisdexamfetamine—Constipation—Captopril—systemic scleroderma	0.000175	0.00263	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000175	0.00263	CcSEcCtD
Lisdexamfetamine—Palpitations—Mycophenolic acid—systemic scleroderma	0.000175	0.00262	CcSEcCtD
Lisdexamfetamine—Skin disorder—Azathioprine—systemic scleroderma	0.000174	0.00261	CcSEcCtD
Lisdexamfetamine—Nervousness—Lisinopril—systemic scleroderma	0.000173	0.00259	CcSEcCtD
Lisdexamfetamine—Affect lability—Prednisone—systemic scleroderma	0.000173	0.00259	CcSEcCtD
Lisdexamfetamine—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000173	0.00259	CcSEcCtD
Lisdexamfetamine—Dry mouth—Leflunomide—systemic scleroderma	0.000172	0.00259	CcSEcCtD
Lisdexamfetamine—Vomiting—Pentoxifylline—systemic scleroderma	0.000172	0.00258	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Prednisone—systemic scleroderma	0.000171	0.00257	CcSEcCtD
Lisdexamfetamine—Convulsion—Mycophenolic acid—systemic scleroderma	0.000171	0.00257	CcSEcCtD
Lisdexamfetamine—Rash—Pentoxifylline—systemic scleroderma	0.000171	0.00256	CcSEcCtD
Lisdexamfetamine—Hypertension—Mycophenolic acid—systemic scleroderma	0.000171	0.00256	CcSEcCtD
Lisdexamfetamine—Dermatitis—Pentoxifylline—systemic scleroderma	0.000171	0.00256	CcSEcCtD
Lisdexamfetamine—Headache—Pentoxifylline—systemic scleroderma	0.00017	0.00254	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000169	0.00254	CcSEcCtD
Lisdexamfetamine—Vision blurred—Lisinopril—systemic scleroderma	0.000168	0.00252	CcSEcCtD
Lisdexamfetamine—Anxiety—Mycophenolic acid—systemic scleroderma	0.000168	0.00252	CcSEcCtD
Lisdexamfetamine—Asthenia—Mometasone—systemic scleroderma	0.000168	0.00251	CcSEcCtD
Lisdexamfetamine—Irritability—Prednisone—systemic scleroderma	0.000168	0.00251	CcSEcCtD
Lisdexamfetamine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000167	0.00251	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000167	0.00251	CcSEcCtD
Lisdexamfetamine—Tremor—Lisinopril—systemic scleroderma	0.000167	0.0025	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000166	0.0025	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Leflunomide—systemic scleroderma	0.000166	0.00249	CcSEcCtD
Lisdexamfetamine—Tachycardia—Leflunomide—systemic scleroderma	0.000165	0.00248	CcSEcCtD
Lisdexamfetamine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000165	0.00247	CcSEcCtD
Lisdexamfetamine—Skin disorder—Leflunomide—systemic scleroderma	0.000164	0.00246	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000163	0.00245	CcSEcCtD
Lisdexamfetamine—Angioedema—Lisinopril—systemic scleroderma	0.000163	0.00244	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Captopril—systemic scleroderma	0.000162	0.00243	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000161	0.00242	CcSEcCtD
Lisdexamfetamine—Anorexia—Leflunomide—systemic scleroderma	0.000161	0.00242	CcSEcCtD
Lisdexamfetamine—Nausea—Pentoxifylline—systemic scleroderma	0.000161	0.00241	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Mometasone—systemic scleroderma	0.00016	0.0024	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000158	0.00237	CcSEcCtD
Lisdexamfetamine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000157	0.00236	CcSEcCtD
Lisdexamfetamine—Palpitations—Lisinopril—systemic scleroderma	0.000157	0.00236	CcSEcCtD
Lisdexamfetamine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000157	0.00236	CcSEcCtD
Lisdexamfetamine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000157	0.00235	CcSEcCtD
Lisdexamfetamine—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000156	0.00234	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000156	0.00234	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Methotrexate—systemic scleroderma	0.000155	0.00232	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000155	0.00232	CcSEcCtD
Lisdexamfetamine—Anorexia—Mycophenolic acid—systemic scleroderma	0.000154	0.00231	CcSEcCtD
Lisdexamfetamine—Insomnia—Leflunomide—systemic scleroderma	0.000153	0.00229	CcSEcCtD
Lisdexamfetamine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.000151	0.00227	CcSEcCtD
Lisdexamfetamine—Anxiety—Lisinopril—systemic scleroderma	0.000151	0.00227	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Leflunomide—systemic scleroderma	0.000151	0.00226	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000151	0.00226	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00015	0.00225	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Leflunomide—systemic scleroderma	0.000149	0.00223	CcSEcCtD
Lisdexamfetamine—Vomiting—Mometasone—systemic scleroderma	0.000149	0.00223	CcSEcCtD
Lisdexamfetamine—Dry mouth—Lisinopril—systemic scleroderma	0.000148	0.00222	CcSEcCtD
Lisdexamfetamine—Rash—Mometasone—systemic scleroderma	0.000147	0.00221	CcSEcCtD
Lisdexamfetamine—Asthenia—Captopril—systemic scleroderma	0.000147	0.00221	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mometasone—systemic scleroderma	0.000147	0.00221	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Leflunomide—systemic scleroderma	0.000147	0.00221	CcSEcCtD
Lisdexamfetamine—Headache—Mometasone—systemic scleroderma	0.000146	0.0022	CcSEcCtD
Lisdexamfetamine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000146	0.00219	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000146	0.00219	CcSEcCtD
Lisdexamfetamine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000146	0.00219	CcSEcCtD
Lisdexamfetamine—Fatigue—Leflunomide—systemic scleroderma	0.000146	0.00219	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000145	0.00218	CcSEcCtD
Lisdexamfetamine—Constipation—Leflunomide—systemic scleroderma	0.000145	0.00217	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000144	0.00216	CcSEcCtD
Lisdexamfetamine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000143	0.00215	CcSEcCtD
Lisdexamfetamine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00215	CcSEcCtD
Lisdexamfetamine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00214	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000142	0.00213	CcSEcCtD
Lisdexamfetamine—Tachycardia—Lisinopril—systemic scleroderma	0.000142	0.00213	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Azathioprine—systemic scleroderma	0.000142	0.00212	CcSEcCtD
Lisdexamfetamine—Skin disorder—Lisinopril—systemic scleroderma	0.000141	0.00212	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00014	0.00211	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Captopril—systemic scleroderma	0.00014	0.00211	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00014	0.0021	CcSEcCtD
Lisdexamfetamine—Irritability—Methotrexate—systemic scleroderma	0.00014	0.0021	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Prednisone—systemic scleroderma	0.00014	0.0021	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000139	0.00209	CcSEcCtD
Lisdexamfetamine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000139	0.00209	CcSEcCtD
Lisdexamfetamine—Nausea—Mometasone—systemic scleroderma	0.000139	0.00208	CcSEcCtD
Lisdexamfetamine—Anorexia—Lisinopril—systemic scleroderma	0.000138	0.00208	CcSEcCtD
Lisdexamfetamine—Weight increased—Prednisone—systemic scleroderma	0.000138	0.00207	CcSEcCtD
Lisdexamfetamine—Constipation—Mycophenolic acid—systemic scleroderma	0.000138	0.00207	CcSEcCtD
Lisdexamfetamine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000138	0.00207	CcSEcCtD
Lisdexamfetamine—Weight decreased—Prednisone—systemic scleroderma	0.000137	0.00206	CcSEcCtD
Lisdexamfetamine—Dizziness—Captopril—systemic scleroderma	0.000136	0.00204	CcSEcCtD
Lisdexamfetamine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000135	0.00203	CcSEcCtD
Lisdexamfetamine—Depression—Prednisone—systemic scleroderma	0.000135	0.00202	CcSEcCtD
Lisdexamfetamine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000135	0.00202	CcSEcCtD
Lisdexamfetamine—Urticaria—Leflunomide—systemic scleroderma	0.000134	0.00202	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Leflunomide—systemic scleroderma	0.000134	0.00201	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000133	0.002	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Prednisone—systemic scleroderma	0.000133	0.00199	CcSEcCtD
Lisdexamfetamine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000132	0.00199	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000132	0.00198	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000132	0.00198	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000132	0.00198	CcSEcCtD
Lisdexamfetamine—Insomnia—Lisinopril—systemic scleroderma	0.000131	0.00197	CcSEcCtD
Lisdexamfetamine—Vomiting—Captopril—systemic scleroderma	0.00013	0.00196	CcSEcCtD
Lisdexamfetamine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00013	0.00195	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Lisinopril—systemic scleroderma	0.00013	0.00194	CcSEcCtD
Lisdexamfetamine—Rash—Captopril—systemic scleroderma	0.000129	0.00194	CcSEcCtD
Lisdexamfetamine—Dermatitis—Captopril—systemic scleroderma	0.000129	0.00194	CcSEcCtD
Lisdexamfetamine—Somnolence—Lisinopril—systemic scleroderma	0.000129	0.00194	CcSEcCtD
Lisdexamfetamine—Headache—Captopril—systemic scleroderma	0.000129	0.00193	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Lisinopril—systemic scleroderma	0.000128	0.00192	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000128	0.00191	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000127	0.00191	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Lisinopril—systemic scleroderma	0.000126	0.0019	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000125	0.00188	CcSEcCtD
Lisdexamfetamine—Fatigue—Lisinopril—systemic scleroderma	0.000125	0.00188	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000125	0.00187	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000125	0.00187	CcSEcCtD
Lisdexamfetamine—Constipation—Lisinopril—systemic scleroderma	0.000124	0.00186	CcSEcCtD
Lisdexamfetamine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000124	0.00186	CcSEcCtD
Lisdexamfetamine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000124	0.00186	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000123	0.00185	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Azathioprine—systemic scleroderma	0.000123	0.00184	CcSEcCtD
Lisdexamfetamine—Nausea—Captopril—systemic scleroderma	0.000122	0.00183	CcSEcCtD
Lisdexamfetamine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000121	0.00182	CcSEcCtD
Lisdexamfetamine—Asthenia—Leflunomide—systemic scleroderma	0.000121	0.00182	CcSEcCtD
Lisdexamfetamine—Hallucination—Prednisone—systemic scleroderma	0.000121	0.00181	CcSEcCtD
Lisdexamfetamine—Dizziness—Azathioprine—systemic scleroderma	0.000118	0.00178	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000117	0.00175	CcSEcCtD
Lisdexamfetamine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000116	0.00174	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Leflunomide—systemic scleroderma	0.000116	0.00174	CcSEcCtD
Lisdexamfetamine—Urticaria—Lisinopril—systemic scleroderma	0.000115	0.00173	CcSEcCtD
Lisdexamfetamine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000115	0.00173	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Lisinopril—systemic scleroderma	0.000115	0.00172	CcSEcCtD
Lisdexamfetamine—Vomiting—Azathioprine—systemic scleroderma	0.000114	0.00171	CcSEcCtD
Lisdexamfetamine—Eye disorder—Prednisone—systemic scleroderma	0.000114	0.0017	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000113	0.0017	CcSEcCtD
Lisdexamfetamine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000113	0.0017	CcSEcCtD
Lisdexamfetamine—Rash—Azathioprine—systemic scleroderma	0.000113	0.00169	CcSEcCtD
Lisdexamfetamine—Dermatitis—Azathioprine—systemic scleroderma	0.000113	0.00169	CcSEcCtD
Lisdexamfetamine—Depression—Methotrexate—systemic scleroderma	0.000113	0.00169	CcSEcCtD
Lisdexamfetamine—Headache—Azathioprine—systemic scleroderma	0.000112	0.00168	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000112	0.00168	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00168	CcSEcCtD
Lisdexamfetamine—Dizziness—Leflunomide—systemic scleroderma	0.000112	0.00168	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000111	0.00166	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00011	0.00166	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00011	0.00165	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Prednisone—systemic scleroderma	0.00011	0.00165	CcSEcCtD
Lisdexamfetamine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000109	0.00163	CcSEcCtD
Lisdexamfetamine—Vomiting—Leflunomide—systemic scleroderma	0.000108	0.00161	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000107	0.00161	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000107	0.0016	CcSEcCtD
Lisdexamfetamine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000107	0.0016	CcSEcCtD
Lisdexamfetamine—Rash—Leflunomide—systemic scleroderma	0.000107	0.0016	CcSEcCtD
Lisdexamfetamine—Dermatitis—Leflunomide—systemic scleroderma	0.000107	0.0016	CcSEcCtD
Lisdexamfetamine—Mental disorder—Prednisone—systemic scleroderma	0.000106	0.0016	CcSEcCtD
Lisdexamfetamine—Nausea—Azathioprine—systemic scleroderma	0.000106	0.0016	CcSEcCtD
Lisdexamfetamine—Headache—Leflunomide—systemic scleroderma	0.000106	0.00159	CcSEcCtD
Lisdexamfetamine—Malnutrition—Prednisone—systemic scleroderma	0.000106	0.00159	CcSEcCtD
Lisdexamfetamine—Asthenia—Lisinopril—systemic scleroderma	0.000104	0.00156	CcSEcCtD
Lisdexamfetamine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000103	0.00154	CcSEcCtD
Lisdexamfetamine—Rash—Mycophenolic acid—systemic scleroderma	0.000102	0.00153	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000102	0.00152	CcSEcCtD
Lisdexamfetamine—Hepatitis—Methotrexate—systemic scleroderma	0.000102	0.00152	CcSEcCtD
Lisdexamfetamine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000101	0.00152	CcSEcCtD
Lisdexamfetamine—Headache—Mycophenolic acid—systemic scleroderma	0.000101	0.00152	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000101	0.00151	CcSEcCtD
Lisdexamfetamine—Nausea—Leflunomide—systemic scleroderma	0.0001	0.00151	CcSEcCtD
Lisdexamfetamine—Vision blurred—Prednisone—systemic scleroderma	9.96e-05	0.0015	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Lisinopril—systemic scleroderma	9.94e-05	0.00149	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methotrexate—systemic scleroderma	9.78e-05	0.00147	CcSEcCtD
Lisdexamfetamine—Agitation—Prednisone—systemic scleroderma	9.72e-05	0.00146	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisone—systemic scleroderma	9.66e-05	0.00145	CcSEcCtD
Lisdexamfetamine—Dizziness—Lisinopril—systemic scleroderma	9.61e-05	0.00144	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—systemic scleroderma	9.6e-05	0.00144	CcSEcCtD
Lisdexamfetamine—Nausea—Mycophenolic acid—systemic scleroderma	9.58e-05	0.00144	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—systemic scleroderma	9.49e-05	0.00142	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—systemic scleroderma	9.42e-05	0.00141	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	9.38e-05	0.00141	CcSEcCtD
Lisdexamfetamine—Vomiting—Lisinopril—systemic scleroderma	9.24e-05	0.00139	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—systemic scleroderma	9.17e-05	0.00138	CcSEcCtD
Lisdexamfetamine—Rash—Lisinopril—systemic scleroderma	9.16e-05	0.00137	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisone—systemic scleroderma	9.16e-05	0.00137	CcSEcCtD
Lisdexamfetamine—Dermatitis—Lisinopril—systemic scleroderma	9.15e-05	0.00137	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—systemic scleroderma	9.15e-05	0.00137	CcSEcCtD
Lisdexamfetamine—Asthenia—Mycophenolate mofetil—systemic scleroderma	9.13e-05	0.00137	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisone—systemic scleroderma	9.13e-05	0.00137	CcSEcCtD
Lisdexamfetamine—Headache—Lisinopril—systemic scleroderma	9.1e-05	0.00137	CcSEcCtD
Lisdexamfetamine—Anxiety—Prednisone—systemic scleroderma	8.97e-05	0.00135	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.94e-05	0.00134	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—systemic scleroderma	8.89e-05	0.00133	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—systemic scleroderma	8.84e-05	0.00133	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	8.71e-05	0.00131	CcSEcCtD
Lisdexamfetamine—Nausea—Lisinopril—systemic scleroderma	8.63e-05	0.00129	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisone—systemic scleroderma	8.63e-05	0.00129	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Prednisone—systemic scleroderma	8.46e-05	0.00127	CcSEcCtD
Lisdexamfetamine—Tachycardia—Prednisone—systemic scleroderma	8.42e-05	0.00126	CcSEcCtD
Lisdexamfetamine—Dizziness—Mycophenolate mofetil—systemic scleroderma	8.42e-05	0.00126	CcSEcCtD
Lisdexamfetamine—Skin disorder—Prednisone—systemic scleroderma	8.38e-05	0.00126	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisone—systemic scleroderma	8.34e-05	0.00125	CcSEcCtD
Lisdexamfetamine—Vision blurred—Methotrexate—systemic scleroderma	8.33e-05	0.00125	CcSEcCtD
Lisdexamfetamine—Anorexia—Prednisone—systemic scleroderma	8.23e-05	0.00123	CcSEcCtD
Lisdexamfetamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	8.09e-05	0.00121	CcSEcCtD
Lisdexamfetamine—Rash—Mycophenolate mofetil—systemic scleroderma	8.03e-05	0.0012	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	8.02e-05	0.0012	CcSEcCtD
Lisdexamfetamine—Headache—Mycophenolate mofetil—systemic scleroderma	7.97e-05	0.0012	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisone—systemic scleroderma	7.8e-05	0.00117	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—systemic scleroderma	7.66e-05	0.00115	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Prednisone—systemic scleroderma	7.6e-05	0.00114	CcSEcCtD
Lisdexamfetamine—Nausea—Mycophenolate mofetil—systemic scleroderma	7.56e-05	0.00113	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Prednisone—systemic scleroderma	7.5e-05	0.00113	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	7.47e-05	0.00112	CcSEcCtD
Lisdexamfetamine—Fatigue—Prednisone—systemic scleroderma	7.44e-05	0.00112	CcSEcCtD
Lisdexamfetamine—Constipation—Prednisone—systemic scleroderma	7.38e-05	0.00111	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—systemic scleroderma	7.21e-05	0.00108	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—systemic scleroderma	7.07e-05	0.00106	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—systemic scleroderma	7e-05	0.00105	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—systemic scleroderma	6.97e-05	0.00105	CcSEcCtD
Lisdexamfetamine—Anorexia—Methotrexate—systemic scleroderma	6.87e-05	0.00103	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisone—systemic scleroderma	6.85e-05	0.00103	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Prednisone—systemic scleroderma	6.82e-05	0.00102	CcSEcCtD
Lisdexamfetamine—Insomnia—Methotrexate—systemic scleroderma	6.52e-05	0.000979	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Methotrexate—systemic scleroderma	6.43e-05	0.000965	CcSEcCtD
Lisdexamfetamine—Somnolence—Methotrexate—systemic scleroderma	6.41e-05	0.000962	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisone—systemic scleroderma	6.36e-05	0.000954	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—systemic scleroderma	6.35e-05	0.000953	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—systemic scleroderma	6.27e-05	0.000941	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	6.23e-05	0.000934	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—systemic scleroderma	6.22e-05	0.000933	CcSEcCtD
Lisdexamfetamine—Asthenia—Prednisone—systemic scleroderma	6.19e-05	0.000929	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Prednisone—systemic scleroderma	5.9e-05	0.000886	CcSEcCtD
Lisdexamfetamine—Urticaria—Methotrexate—systemic scleroderma	5.73e-05	0.00086	CcSEcCtD
Lisdexamfetamine—Dizziness—Prednisone—systemic scleroderma	5.71e-05	0.000856	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—systemic scleroderma	5.7e-05	0.000855	CcSEcCtD
Lisdexamfetamine—Vomiting—Prednisone—systemic scleroderma	5.49e-05	0.000823	CcSEcCtD
Lisdexamfetamine—Rash—Prednisone—systemic scleroderma	5.44e-05	0.000816	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisone—systemic scleroderma	5.44e-05	0.000816	CcSEcCtD
Lisdexamfetamine—Headache—Prednisone—systemic scleroderma	5.41e-05	0.000811	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methotrexate—systemic scleroderma	5.31e-05	0.000797	CcSEcCtD
Lisdexamfetamine—Asthenia—Methotrexate—systemic scleroderma	5.17e-05	0.000776	CcSEcCtD
Lisdexamfetamine—Nausea—Prednisone—systemic scleroderma	5.13e-05	0.000769	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—systemic scleroderma	4.93e-05	0.00074	CcSEcCtD
Lisdexamfetamine—Dizziness—Methotrexate—systemic scleroderma	4.77e-05	0.000716	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—systemic scleroderma	4.59e-05	0.000688	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—systemic scleroderma	4.55e-05	0.000682	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—systemic scleroderma	4.54e-05	0.000682	CcSEcCtD
Lisdexamfetamine—Headache—Methotrexate—systemic scleroderma	4.52e-05	0.000678	CcSEcCtD
Lisdexamfetamine—Nausea—Methotrexate—systemic scleroderma	4.28e-05	0.000643	CcSEcCtD
